bioAffinity Technologies (BIAF) Cost of Revenue (2022 - 2025)

bioAffinity Technologies (BIAF) has 4 years of Cost of Revenue data on file, last reported at $900126.0 in Q4 2025.

• Cost of Revenue for Q4 2025 came in at $900126.0, down 42.38% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.2 million (down 29.36% YoY), and the FY2025 annual result was $4.2 million, down 29.36% from the prior year.
• Cost of Revenue retreated to $900126.0 in Q4 2025 per BIAF's latest filing, from $942211.0 in the prior quarter.
• Over five years, Cost of Revenue peaked at $1.7 million in Q4 2023 and troughed at $87.0 in Q1 2023.
• A 4-year average of $796775.0 and a median of $942211.0 in 2025 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2024 and 2025: Cost of Revenue surged 1808452.87% in 2024, then tumbled 42.38% in 2025.
• A 4-year view of Cost of Revenue shows it stood at $175.0 in 2022, then surged by 951248.0% to $1.7 million in 2023, then declined by 6.17% to $1.6 million in 2024, then plunged by 42.38% to $900126.0 in 2025.
• Business Quant data shows BIAF's Cost of Revenue at $900126.0 in Q4 2025, $942211.0 in Q3 2025, and $1.0 million in Q2 2025.